Professor Robert MacLaren (Overall Winner & Winner of Inspiring Leader Category)
Gene therapy may help to slow or even stop the degeneration in genetic eye diseases. Research led by Professor Robert MacLaren led to the spinout of Nightstar which was acquired by Biogen for $877 million in early 2019 – just five years after its founding. The deal ranks as the third most valuable British biotech exit in the last two decades. Read about his work here.
Watch the talk at: https://youtu.be/JiebkKa7m8M